2026-01-22 - Analysis Report
**Company Overview:**
AbbVie is a multinational biopharmaceutical company headquartered in the United States that specializes in developing and manufacturing a range of pharmaceuticals and vaccines.

**Return Rate Analysis:**
| Ticker | Return Rate |
| --- | --- |
| ABBV | 177.76% |
| VOO (S&P 500) | 91.55% |
| Divergence | 82.20 |
| Relative Divergence | 65.80% |

The return rate of ABBV is higher than that of VOO (S&P 500) by 82.20. The relative divergence indicates that ABBV is currently at the top 65.80% percentile of past data.

**Alpha, Beta Analysis:**

| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019 | 42.0% | 21.6% | 24.0% | 1.1 | 156.5B |
| 2018-2020 | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021 | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022 | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023 | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024 | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025 | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

**Stock Price Fluctuations:**

| Moving Average | Price |
| --- | --- |
| 5-day SMA | $216.64 |
| 20-day SMA | $224.03 |
| 60-day SMA | $225.36 |
| Close | $216.15 |
| Last-market | {'price': 216.15, 'previousClose': 214.04, 'change': 0.99} |

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**
| Indicator | Value |
| --- | --- |
| RSI | 36.31 |
| PPO | -0.53 |
| Market Risk Indicator (MRI) | 0.80 |
| Risk Level | Medium |
| Recent (20 days) relative divergence change | -2.80 |
| 7-day Rank change | 2 (+) |
| 7-day Dynamic Expected Return change | 0.60 (+) |
| Expected Return (%) | 40.20% |

The recent market risk indicator suggests a medium investment risk. The RSI indicator is at a relatively low value (36.31), indicating potential overselling. The PPO indicator is highly negative (-0.53), indicating potential price movement.

**News & Significant Events:**

* [2026-01-21] AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market - Finviz (link)
* [2026-01-21] Price Over Earnings Overview: AbbVie - AbbVie (NYSE:ABBV) - Benzinga (link)
* [2026-01-15] AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance (link)
* [2026-01-18] Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - The Motley Fool (link)
* [2026-01-21] Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV) - The Globe and Mail (link)
* [2026-01-20] The Long-Term Investment Value of Eli Lilly, AbbVie, and Intuitive Surgical - NAI500 (link)

**Analyst Opinions:**

* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): 245.22 / 289.00 / 184.00

**Comprehensive Analysis:**
The analysis indicates that ABBV has a higher return rate than VOO (S&P 500), with a cumulative return of 177.76%. The relative divergence suggests that ABBV is currently at the top 65.80% percentile of past data. The Alpha, Beta analysis indicates that ABBV has had varying levels of success in recent years. The stock price fluctuations suggest a potential uptrend. The RSI indicator is at a relatively low value, indicting potential overselling, while the PPO indicator is highly negative, indicating potential price movement. The recent market risk indicator suggests a medium investment risk. The analyst opinions suggest a Buy rating with a target price between $184.00 and $289.00. The news articles suggest that AbbVie is looking to deepen its push into the rapidly growing obesity-treatment market and is a top pick among analysts.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.